Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492103 | 1.00 | GPR35 (0.38) | GPR35NUDT1ALDH1A1DYRK1AHTT | |
| SCHEMBL1613412 | 0.79 | ALDH1A1 (0.37) | NUDT1ALDH1A1DYRK1AHTTGSK3B | |
| SCHEMBL29497257 | 0.73 | LATS1 (0.32) | — | |
| SCHEMBL21903872 | 0.72 | KDM1A (0.33) | ALDH1A1KDM1A | |
| SCHEMBL21903886 | 0.71 | AR (0.36) | GPR35ALDH1A1GSK3B | |
| SCHEMBL14025078 | 0.69 | POLB (0.53) | ALDH1A1DYRK1AMEN1KMT2AKDM1A | |
| SCHEMBL11172727 | 0.69 | ALDH1A1 (0.49) | GPR35ALDH1A1DYRK1AHTTMEN1 | |
| SCHEMBL21903939 | 0.69 | XDH (0.46) | GPR35DYRK1AKDM1AIDO1 | |
| SCHEMBL31492077 | 0.69 | XDH (0.46) | GPR35DYRK1AKDM1AIDO1 | |
| SCHEMBL28601707 | 0.66 | XDH (0.46) | GPR35ALDH1A1DYRK1AKDM1AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877364-B1 | ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3877364-A1 | ROCK KINASE INHIBITORS | Cervello Therapeutics, LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-08-20 | — | — | US | disclosed |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-08-20 | — | — | US | disclosed |
| US-10745381-B2 | Substituted isoquinolines and phthalazines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745381-B2 | Substituted isoquinolines and phthalazines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200140412-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-05-07 | — | — | US | disclosed |
| US-20200140412-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745381-B2 | Substituted isoquinolines and phthalazines as rock kinase inhibitors | ROCK1, ROCK2, CIT | GPR35 1214/4885NUDT1 2629/4885ALDH1A1 4264/4885 |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | GPR35 1730/4885NUDT1 2324/4885ALDH1A1 4101/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | GPR35 1730/4885NUDT1 2324/4885ALDH1A1 4101/4885 |
| US-20200140412-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | GPR35 2251/4885NUDT1 2894/4885ALDH1A1 3759/4885 |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | GPR35 2251/4885NUDT1 2894/4885ALDH1A1 3759/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | GPR35 1730/4885NUDT1 2324/4885ALDH1A1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.